Non-Hodgkin B-cell lymphoma
Conditions
Interventions
case series:N/A
Sponsors
Harbin Institute of Hematology and Oncology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years, male or female; 2. Non-Hodgkin B-cell lymphoma confirmed by histopathology; 3. The patient volunteered to participate in the study and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with allergic constitution or known allergy to any active component, excipient or mouse protein of rituximab; 2. Patients with severe active infection or severe impairment of immune response (such as hypoglobinemia, and severe reduction of CD4 or CD8 cell count); 3, severe heart failure (NYHA classification IV level); 4. Other serious diseases of important organs (cardiovascular, liver, kidney) and blood and endocrine system, and other malignant tumors; 5. Serious mental illness; 6. Pregnant or lactating women and men or women who intend to conceive recently; 7. The estimated survival time is less than 6 months; 8. The investigator determined that the patient was not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution of non-Hodgkin B cell lymphoma subtypes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR) and complete response rate (CR) of rituximab or combination chemotherapy for non-hodgkin B-cell lymphoma;Rates of progression-free survival (PFS) at 1, 3, and 5 years of rituximab treatment with various subtypes of NHL;Overall survival (OS) rates for 1, 3, and 5 year treatment with rituximab for each subtype of NHL; | — |
Countries
China
Contacts
Public ContactMa Jun
Harbin Institute of Hematology and Oncology
Outcome results
None listed